fanhdi 25 iuml (factor viii)
medici medical ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 250 iu - coagulation factor viii - coagulation factor viii - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a .fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.
fanhdi 100 iuml 1500 iu (factor viii)
medici medical ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 1500 iu/dose - factor viii inhibitor bypassing activity - factor viii inhibitor bypassing activity - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a . fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.
octanate 50 iu/ml inj. sol. (pwdr. + solv.) i.v. vial
octapharma benelux sa-nv - human coagulation factor viii 50 iu/ml - powder and solvent for solution for injection - 50 iu/ml - human coagulation factor viii 50 iu/ml - coagulation factor viii
fanhdi 50 iuml (factor viii)
medici medical ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 500 iu - coagulation factor viii - coagulation factor viii - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a . fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.
fanhdi 100 iuml (factor viii)
medici medical ltd, israel - factor viii (human) - powder for solution for injection - factor viii (human) 1000 iu - coagulation factor viii - coagulation factor viii - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a . fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.
haemoctin sdh 250 iu
kamada ltd, israel - human plasma coagulation factor viii - powder for solution for injection - human plasma coagulation factor viii 50 iu/ml - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding: in patients with haemophilia a (congenital factor viii deficiency) in patient with acquired factor viii deficiency. haemoctin is not effective in controlling the bleeding of patients with von willebrond`s disease.
immunate 250 iu fviii/190 iu vwf powder and solvent for solution for injection
takeda manufacturing austria ag industriestrasse 67, a-1221, vienna, austria - factor viii, human, von willebrand - powder and solvent for solution for injection - factor viii, human 250 iu von willebrand factor, human 190 iu - antihemorrhagics
octanate 50 iu/ml inj. sol. (pwdr. + solv.) i.v. vial
octapharma benelux sa-nv - human coagulation factor viii 50 iu/ml - powder and solvent for solution for injection - 50 iu/ml - human coagulation factor viii 50 iu/ml - coagulation factor viii
octanate 50iu/ml powder and solvent for solution for injection (5ml vial)
octapharma (ip) sprl alle de la recherche 65, 1070 (anderlecht), belgium - factor viii, human - powder and solvent for solution for injection - factor viii, human 50 iu/ml - antihemorrhagics
optivate 250iu powder and solvent for solution for injection, human coagulation factor viii
bpl bioproducts laboratory gmbh dornhofstraße 34, 63263 neu-isenburg,, germany - factor viii, human, von willebrand - powder and solvent for solution for injection - factor viii, human 250 iu von willebrand factor, human 430 iu - antihemorrhagics